Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2004-09-29
2009-08-25
Chong, Kimberly (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024310, C435S006120, C435S325000, C435S375000, C514S04400A
Reexamination Certificate
active
07579455
ABSTRACT:
The invention relates to therapeutic antisense oligonucleotides directed against genes coding for phosphodiesterase (PDEs) and the use of these in combination. These antisense oligonucleotides may be used as analytical tools and/or as therapeutic agents in the treatment of disease associated with reduced cellular cAMP in a patient, such as inflammatory diseases of the respiratory tract including, for example, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, bronchitis, chronic bronchitis, silicosis, pulmonary fibrosis, lung allograft rejection, allergic rhinitis and chronic sinusitis as well as other conditions in which an increase in cyclic AMP or a decrease in PDE levels is beneficial.
REFERENCES:
patent: 5734039 (1998-03-01), Calabretta et al.
patent: 5885834 (1999-03-01), Epstein
patent: 6165789 (2000-12-01), Monia et al.
patent: 6348450 (2002-02-01), Tang et al.
patent: 7022849 (2006-04-01), Pitts et al.
patent: 2003/0220273 (2003-11-01), Bennett et al.
patent: WO 97/35989 (1997-10-01), None
patent: 00/40714 (2000-07-01), None
patent: 02/22661 (2002-03-01), None
patent: 03/012030 (2003-02-01), None
Weintraub et al. Antisense RNA and DNA. Scientific American, Jan. 1990: 40-46.
Nemoz et al. Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells. FEBS Letters 1996, vol. 384: 97-102.
Wang et al. Cloning, Characterization, and Tissue Distribution of Mouse Phosphodiesterase 7A1. Biochemical and Biophysical Research Communications 2000, vol. 276: 1271-1277.
Li et al. CD3- and CD28 dependent induction of PDE7 Required for T Cell Activation. Science 1999, vol. 283: 848-851.
Muller et al. Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. TiPS Aug. 1996, vol. 17: 294-298.
Epstein, P., “Antisense Inhibition of Phosphodiesterase Expression,”Methods: A Companion to Methods in Enzymology14, 21-33 (1998), Article No. ME970562. Academic Press.
Soderling, S. et al. “Regulation of cAMP and cGMP signaling: new Phosphodiesterases and new functions.”Current Opinion in Cell Biology 2000, 12:174-179.
Mackenzie, S. et al. “Stimulation of p70S6 kinase via a growth hormone-controlled phosphatidylinositol 3-kinase pathway leads to the activation of a PDE4A cyclic AMP-specific phosphodiesterase in 3T3-F442A preadipocytes”.Proc. National Academic Science, USA. vol. 95, pp. 3549-3554, Mar. 1998.
Li, Linsong. et al. “CD3- and CD28-Dependent Induction of PDE7 Required for T Cell Activation”.Science, vol. 283, Feb. 5, 1999, pp. 848-851.
D'Anjou Helene
Paolo Renzi
Zemzoumi Khalid
Chong Kimberly
Nixon & Peabody LLP
Topigen Pharmaceutique Inc.
LandOfFree
Oligonucleotide compositions and methods for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotide compositions and methods for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotide compositions and methods for treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4084045